NIASPAN TITRATION STARTER PACK
Clinical safety rating
cautionComprehensive clinical and safety monograph for NIASPAN TITRATION STARTER PACK (NIASPAN TITRATION STARTER PACK).
Comprehensive clinical and safety monograph for NIASPAN TITRATION STARTER PACK (NIASPAN TITRATION STARTER PACK).
Adjunct to diet in primary hyperlipidemia (mixed dyslipidemia) and hypertriglyceridemiaReduction of risk of myocardial infarction in patients with established coronary artery disease (off-label use: prevention of cardiovascular events, though evidence is limited)
Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL by inhibiting diacylglycerol acyltransferase-2 (DGAT-2) and reducing free fatty acid mobilization from adipose tissue via inhibition of lipolysis. It also increases HDL by reducing hepatic clearance of apoA-I.
| Metabolism | Primarily hepatic metabolism via two pathways: conjugation (low-affinity, high-capacity pathway) and amidation (high-affinity, low-capacity pathway). At low doses, amidation by nicotinamide phosphoribosyltransferase (NAMPT) is the major route; at high doses, conjugation with glycine (to nicotinuric acid) predominates. |
| Excretion | Renal: approximately 60-76% of a dose excreted as unchanged drug and metabolites; biliary/fecal: less than 10% |
| Half-life | Terminal elimination half-life is approximately 2-4 hours for immediate-release niacin; for extended-release (Niaspan), it is 2-6 hours. However, the pharmacodynamic effect on lipids may persist beyond plasma elimination due to prolonged receptor interaction. |
| Protein binding | Less than 20% bound to plasma proteins (mainly albumin) at therapeutic concentrations. |
| Volume of Distribution | Approximately 0.3-0.5 L/kg, suggesting distribution into total body water and some tissue binding. |
| Bioavailability | Extended-release tablets: absolute bioavailability is not established due to extensive first-pass metabolism, but systemic exposure (AUC) is approximately 30-60% of an equivalent intravenous dose; food increases bioavailability by 20-30%. |
| Onset of Action | Oral extended-release: lipid-lowering effects are observed within days to weeks, with maximal effect typically seen after 4-8 weeks of continuous dosing. |
| Duration of Action | Oral extended-release: the lipid-lowering effect lasts for the dosing interval (24 hours) with once-daily administration; clinical effects on HDL and triglycerides may persist for weeks after discontinuation. |
| Molecular Weight | 123.11 |
Initial: 500 mg orally once daily at bedtime. Titrate: increase by 500 mg every 4 weeks to a maximum of 2000 mg once daily. Maintenance: 1000-2000 mg once daily.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not recommended in patients with severe renal impairment (GFR < 30 mL/min) or on dialysis due to risk of niacin accumulation. |
| Liver impairment | Contraindicated in patients with active liver disease or unexplained transaminase elevations. In Child-Pugh A or B, use with caution and monitor liver function; no specific dose recommendations. Child-Pugh C: contraindicated. |
| Pediatric use | Safety and efficacy not established in pediatric patients < 16 years; no approved dosing. |
| Geriatric use | No specific dose adjustment; start at low end of dosing range and titrate slowly due to increased risk of adverse effects (e.g., flushing, hypotension) in elderly. |
| 1st trimester | Niacin is generally avoided in first trimester unless benefits outweigh risks. Animal studies show no teratogenic effects but fetal development may be affected due to maternal metabolic changes. |
| 2nd trimester | Use with caution; monitor for hepatotoxicity and hyperglycemia. Niacin can cause flushing and may affect placental blood flow. |
| 3rd trimester | Avoid near term as high doses can cause maternal liver toxicity and potential fetal distress. Use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for NIASPAN TITRATION STARTER PACK (NIASPAN TITRATION STARTER PACK).
| Placental transfer | Niacin crosses the placenta. Evidence suggests limited transfer at normal doses, but high doses may lead to significant fetal exposure. |
| Breastfeeding | Niacin is excreted into breast milk in small amounts. High doses may cause adverse effects in the infant. Monitor infant for flushing, gastrointestinal disturbance, or liver function changes. Use caution with doses exceeding the recommended dietary allowance. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Niacin (nicotinic acid) is generally considered to have low teratogenic potential. Animal studies have not shown evidence of fetal harm. There are limited human data; however, niacin is an essential vitamin, and deficiency is associated with adverse pregnancy outcomes. No specific trimester-specific risks are established. Use only if clearly needed and no safer alternative exists. |
| Fetal Monitoring | Monitor liver function tests (LFTs) and serum uric acid levels periodically due to potential for hepatotoxicity and hyperuricemia. In pregnancy, monitor fetal growth and well-being via ultrasound if prolonged use is required. Monitor maternal blood glucose due to increased insulin resistance in pregnancy. |
| Fertility Effects | No known adverse effects on human fertility. Niacin is an essential nutrient; deficiency may impair reproductive function. High doses have not been associated with fertility impairment in animal studies. |
■ FDA Black Box Warning
Severe hepatotoxicity, particularly with sustained-release niacin. Acute hepatic necrosis has been reported. Combination with statins increases risk of myopathy/rhabdomyolysis.
| Serious Effects |
Active liver disease or unexplained transaminase elevationsActive peptic ulcer diseaseArterial hemorrhageHypersensitivity to niacin or any component
| Precautions | Elevations in liver enzymes (monitor periodically), risk of hepatotoxicity, flushing and pruritus (pretreatment with aspirin may help), activation of peptic ulcer, hyperuricemia/gout, hyperglycemia (may worsen diabetes), orthostatic hypotension, rare cases of atrial fibrillation and other arrhythmias. |
| Food/Dietary | Take with a low-fat snack or meal to reduce GI upset and flushing. Avoid grapefruit juice? Not applicable. Avoid alcohol concurrently, especially hot alcoholic beverages, as they may exacerbate flushing and hypotension. No known interaction with dairy or high-fiber foods. Low-fat meal is recommended (e.g., skim milk, toast, fruit) rather than high-fat meals, which can increase flushing. |
| Clinical Pearls | NIASPAN (niacin ER) initiates flushing via prostaglandin mediation; pre-treat with aspirin (325 mg) 30 minutes prior to reduce prostaglandin synthesis. Titrate over 4 weeks: 500 mg HS weeks 1-4, then 1000 mg HS weeks 5-8. Dose titration minimizes flushing. Avoid concurrent statins due to increased myopathy risk. Monitor LFTs: transaminase elevations >3x ULN require discontinuation. Check fasting glucose at baseline and periodically; new-onset diabetes or worsening glycemic control possible. Consider niacin as second-line for patients not at goal on statins. Contraindicated in active peptic ulcer disease, arterial bleeding, hepatic impairment, or unexplained LFT elevations. |
| Patient Advice | Take NIASPAN exactly as prescribed, typically at bedtime with a low-fat snack or meal to reduce flushing. · Flushing (warmth, redness, tingling) is common but usually decreases over time; taking aspirin 30 minutes before may help. · Do not skip doses; if a dose is missed, do not double the next dose. Resume regular schedule. · Avoid alcohol and hot beverages near the time of dosing as they may worsen flushing. · Report severe flushing, itching, skin rash, dizziness, palpitations, or jaundice to your provider. · NIASPAN may increase blood sugar in diabetic patients; monitor blood glucose closely and report changes. · Keep all appointments for blood tests to monitor liver function and blood sugar. · Store at room temperature away from moisture and heat. |
Loading safety data…